Poolbeg Pharma plc – Interim results for the six months to 30 June 2024
Lead development candidate (POLB 001) on track with positive data demonstrating efficacy
Independent research endorses potential US$10bn market opportunity for POLB 001 in cancer immunotherapy-induced CRS
Patent portfolio significantly strengthened & expanded
Continued focus on high value programmes & partnerships to develop & commercialise assets
Strong Balance Sheet – cash balance of £10.1m
Experienced leadership team with track record of delivering significant value
18 September 2024- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces its unaudited interim results for the six months to 30 June 2024 (“H1 24”).
